Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net revenue	$ 183,774	$ 172,826	$ 361,009	$ 328,579
Operating expenses:
Cost of revenue	85,687	63,938	152,554	120,653
Research and development	41,228	27,025	72,324	85,221
Selling, general and administrative	88,745	52,944	153,266	116,426
Total operating expenses	215,660	143,907	378,144	322,300
(Loss) income from operations	(31,886)	28,919	(17,135)	6,279
Co-promotion and profit share income	7,326	4,068	13,346	7,818
Interest expense	(3,892)	(3,704)	(7,752)	(7,377)
Other (expense) income	(150)	605	29	803
(Loss) income before income taxes	(28,602)	29,888	(11,512)	7,523
Benefit (provision) for income taxes	23,428	(11,854)	1,333	(1,095)
(Loss) income	(5,174)	18,034	(10,179)	6,428
Net loss attributable to non-controlling interest	17	60	26	93
Net (loss) income attributable to The Medicines Company	$ (5,157)	$ 18,094	$ (10,153)	$ 6,521
Basic (loss) income per common share attributable to The Medicines Company (USD per share)	$ (0.08)	$ 0.33	$ (0.16)	$ 0.12
Diluted (loss) income per common share attributable to The Medicines Company (USD per share)	$ (0.08)	$ 0.30	$ (0.16)	$ 0.11
Weighted average number of common shares outstanding:
Basic (shares)	64,400	55,553	64,277	54,804
Diluted (shares)	64,400	60,261	64,277	59,154